Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

101. The Use of CT-Guided Marking for the Laparoscopic Resection of a Solitary Retroperitoneal Metastasis of Colon Cancer Full Text available with Trip Pro

to the tumor by the radiologist. During the surgery, the marker was clearly identified and the cutting line was determined to ensure a sufficient surgical margin. The tumor was laparoscopically resected as planned. The histopathologic diagnosis was adenocarcinoma, compatible with metastasis of colon cancer. The postoperative course was uneventful and the patient remained free of disease at 10 months after surgery. Conclusion: When resecting small tumors or tumors with an irregular margin, a marking (...) The Use of CT-Guided Marking for the Laparoscopic Resection of a Solitary Retroperitoneal Metastasis of Colon Cancer Background: CT-guided marking technique is rarely used in abdominal or urologic surgery. We developed and performed a marking technique for a small tumor, undetectable by ultrasound, using CT guidance before laparoscopic resection of the tumor. Case Presentation: A 73-year-old woman with a history of breast cancer underwent right colectomy with D3 lymph node dissection

2018 Journal of endourology case reports

102. Review gastrointestinal stromal tumors: to prospect the next decade Full Text available with Trip Pro

Review gastrointestinal stromal tumors: to prospect the next decade 30148231 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Review gastrointestinal stromal tumors: to prospect the next decade. 46 10.21037/tgh.2018.07.07 Kanda Tatsuo T Sanjo General Hospital, Niigata, Japan. (Email: kandat@herb.ocn.ne.jp). eng Journal Article 2018 07 23 China Transl Gastroenterol Hepatol 101683450 2415-1289 Conflicts of Interest: The author has no conflicts

2018 Translational gastroenterology and hepatology

103. Colorectal sarcoma: more than a gastrointestinal stromal tumor Full Text available with Trip Pro

Colorectal sarcoma: more than a gastrointestinal stromal tumor Primary colorectal sarcomas have been defined as a rare and diverse group of mesenchymal cancers distinct from gastrointestinal stromal tumors (GISTs). Primary colorectal sarcomas have been recognized as a distinct entity from GISTs due to the dramatically worse prognosis these sarcomas carry. Also, primary colorectal sarcomas when compared to the more common colorectal adenocarcinoma, demonstrate more aggressive biology, present (...) at a younger age and carry worse outcomes. At this time, surgery remains the mainstay of treatment and adjuvant chemotherapy has an unclear role in treatment of primary colorectal sarcoma. This paper attempts to review the available data regarding primary colorectal sarcomas.

2018 Translational gastroenterology and hepatology

104. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer Full Text available with Trip Pro

initially unresectable and previously untreated RAS and BRAF wild-type metastatic colorectal cancer patients are randomised to receive a standard treatment with mFOLFOX6 plus panitumumab or an experimental regimen with modified FOLFOXIRI (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, L-leucovorin 200 mg/m2, 5-fluoruracil 2400 mg/m2 48-hour continuous infusion) plus panitumumab up to 12 cycles, followed by panitumumab plus 5-fluorouracil and L-leucovorin until disease progression. The primary endpoint (...) TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen

2018 ESMO open Controlled trial quality: uncertain

105. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era Full Text available with Trip Pro

Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era The incidence, treatment and outcome of patients with newly diagnosed gastrointestinal stromal tumour (GIST) were studied in an era known for advances in diagnosis and treatment.Nationwide population-based data were retrieved from the Netherlands Cancer Registry. All patients with GIST diagnosed between 2001 and 2012 were included. Primary treatment, defined as any treatment (...) compared with 88·8 (86·0 to 91·4) per cent in those with non-metastatic GIST.This population-based nationwide study found an incidence of GIST in the Netherlands of approximately 8 per million person-years. One in five patients presented with metastatic disease, but relative survival improved significantly over time for all patients with GIST in the imatinib era.© 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.

2018 EvidenceUpdates

106. Bowel Obstruction and Ventral Hernia After Laparoscopic Versus Open Surgery for Rectal Cancer in A Randomized Trial (COLOR II) (Abstract)

Bowel Obstruction and Ventral Hernia After Laparoscopic Versus Open Surgery for Rectal Cancer in A Randomized Trial (COLOR II) The aim of this study was to evaluate the risk of bowel obstruction, incisional, and parastomal hernia following laparoscopic versus open surgery for rectal cancer.Laparoscopic surgery for rectal cancer has been adopted worldwide, after trials reported similar oncological outcomes compared with open surgery. Little is known about long-term morbidity, including bowel (...) in risk of bowel obstruction, incisional, or parastomal hernia following laparoscopic or open surgery for rectal cancer.Based on long-term morbidity outcomes, laparoscopic surgery for rectal cancer could be considered a routine technique as there are no differences with open surgery.

2018 EvidenceUpdates

107. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial (Abstract)

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial Purpose Given the cumulative neurotoxicity associated with oxaliplatin, a shorter duration of adjuvant therapy, if equally efficacious, would be advantageous for patients and health-care systems. Methods The Three or Six Colon Adjuvant trial is an open-label, phase III, multicenter, noninferiority trial randomizing patients with high-risk stage II or stage III colon cancer (...) . Conclusion The Three or Six Colon Adjuvant trial failed to formally show noninferiority of 3 versus 6 months of treatment to the predefined margin of 20% relative increase. The results depended on the adjuvant regimen and risk. For CAPOX, 3 months were as good as 6 months; for FOLFOX, 6 months added extra benefit. Counter-intuitively, the low-risk patients benefitted more than the high-risk population from the 6-month duration. The choice of regimen and duration should depend on patient characteristics

2018 EvidenceUpdates

108. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial Full Text available with Trip Pro

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. Methods In International Duration Evaluation of Adjuvant (...) Chemotherapy (IDEA) France, as part of the IDEA international collaboration, patient with colon cancer patients were randomly assigned to 3 and 6 months of modified FOLFOX6 (mFOLFOX6: infusional fluorouracil, leucovorin, and oxaliplatin) or capecitabine plus oxaliplatin (CAPOX) by physician choice. The primary end point was disease-free survival (DFS), and analyses were descriptive. Results A total of 2,010 eligible patients received either 3 or 6 months of chemotherapy (modified intention-to-treat

2018 EvidenceUpdates

109. Colorectal cancer

Colorectal cancer Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) . Also read , explaining issues with the system. NOTE : Chrome is the best browser to use! To get started, type a condition/disease into the search box above. Here are some examples to get you started: Building Evidence Map X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2018 Trip Evidence Maps

110. The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Statement R. Goodwin, C. Agbassi, E. Kennedy, J. Biagi, R. Wong, S. Welch, S. Berry, and the Gastrointestinal Disease Site Group Report Date: July 3, 2018 This document describes the CCO- Gastrointestinal Cancer Disease Site Group endorsement of The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement published in 2017 by Abrahao et al. The original publication is available at Current Oncology Vol 24, No 6 (2017) For information (...) , Agbassi C, Kennedy E, Biagi J, Wong R, Welch S, Berry S, and the Gastrointestinal Disease Site Group. The Role of Primary Tumour Location in the selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement. Toronto (ON): Cancer Care Ontario; 2018 May. Program in Evidence-based Care Guideline No.: 2-31. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced

2018 Cancer Care Ontario

111. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options.To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with metastatic CRC.FRESCO (Fruquintinib Efficacy and Safety in 3+ Line (...) Colorectal Cancer Patients) was a randomized, double-blind, placebo-controlled, multicenter (28 hospitals in China), phase 3 clinical trial. From December 2014 to May 2016, screening took place among 519 patients aged 18 to 75 years who had metastatic CRC that progressed after at least 2 lines of chemotherapy but had not received VEGFR inhibitor therapy; 416 met the eligibility criteria and were stratified by prior anti-VEGF therapy and K-ras status. The final date of follow-up was January 17, 2017

2018 JAMA Controlled trial quality: predicted high

112. Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials Full Text available with Trip Pro

Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials Surgical resection is the only option of cure for patients with metastatic colorectal cancer. Risk of recurrence after metastasectomy is around 75%. Use of adjuvant chemotherapy after metastasectomy is controversial.To address whether adjuvant systemic therapy after colorectal cancer metastasectomy offers any survival benefit compared (...) no overall survival (OS) benefit with the use of postoperative single-agent fluoropyrimidines compared with surgery alone, even if a trend for benefit was observed (relative hazard (RH)=0.781, 95% CI 0.593 to 1.030, p=0.080). Significant disease-free survival benefit with the use of postoperative chemotherapy was observed (RH=0.645, 95% CI 0.509 to 0.818, p=0.001). No quality of life (QL) data were available. All trials showed accrual delay, two stopped and one recruiting after 10 years. Long follow-up

2018 ESMO open

113. Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change? Full Text available with Trip Pro

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change? 29942667 2019 01 30 2059-7029 3 4 2018 ESMO open ESMO Open Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change? e000392 10.1136/esmoopen-2018-000392 Roda Desamparados D CIBERONC, Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain. Ciardiello Fortunato F Oncologia Medica, Dipartimento di Internistica Clinica e (...) Sperimentale 'F. Magrassi', Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Cervantes Andrés A CIBERONC, Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain. eng Editorial 2018 06 20 England ESMO Open 101690685 2059-7029 colon cancer Competing interests: None declared. 2018 04 30 2018 05 01 2018 6 27 6 0 2018 6 27 6 0 2018 6 27 6 1 epublish 29942667 10.1136/esmoopen-2018-000392 esmoopen-2018-000392 PMC6012558 Ann Oncol. 2017

2018 ESMO open

114. Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations Full Text available with Trip Pro

Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations 30050993 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations . 33 10.21037/tgh.2018.06.03 Yeh Chun-Nan CN Department of Surgery, GIST team (...) , Chang Gung Memorial Hospital and University, Taoyuan, Taiwan. eng Journal Article Comment 2018 06 19 China Transl Gastroenterol Hepatol 101683450 2415-1289 Transl Gastroenterol Hepatol. 2018 Feb 28;3:12 29552663 Conflicts of Interest: The author has no conflicts of interest to declare. 2018 05 27 2018 06 11 2018 7 28 6 0 2018 7 28 6 0 2018 7 28 6 1 epublish 30050993 10.21037/tgh.2018.06.03 tgh-03-2018.06.03 PMC6043756 Cancer Res Treat. 2017 Apr;49(2):350-357 27456941 Lancet. 2013 Jan 26;381(9863

2018 Translational gastroenterology and hepatology

115. Role of chemotherapy in resectable liver metastases from colorectal cancer: food for thought from pooled evidence Full Text available with Trip Pro

Role of chemotherapy in resectable liver metastases from colorectal cancer: food for thought from pooled evidence 29942665 2019 01 30 2059-7029 3 4 2018 ESMO open ESMO Open Role of chemotherapy in resectable liver metastases from colorectal cancer: food for thought from pooled evidence. e000367 10.1136/esmoopen-2018-000367 Mauri Davide D Department of Medical Oncology, University Medical School of Ioannina, Ioannina, Greece. Filis Panagiotis P Department of Medical Oncology, University Medical (...) 2018 05 01 2018 6 27 6 0 2018 6 27 6 0 2018 6 27 6 1 epublish 29942665 10.1136/esmoopen-2018-000367 esmoopen-2018-000367 PMC6012563 Lancet Oncol. 2013 Nov;14(12):1208-15 24120480 J Clin Oncol. 2007 Oct 10;25(29):4575-80 17925551 Neoplasia. 2017 Feb;19(2):93-99 28088688 J Clin Oncol. 2006 Nov 1;24(31):4976-82 17075115 Surg Clin North Am. 2002 Oct;82(5):1075-90, x-xi 12507210 BMC Cancer. 2015 Mar 26;15:180 25884448 Lancet Oncol. 2014 May;15(6):601-11 24717919

2018 ESMO open

116. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer Full Text available with Trip Pro

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain (...) ineffective alone in microsatellite stable tumour. 5-Fluorouracil and oxaliplatin were known to present immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T) is a mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This study is designed to evaluate whether the addition of PD-L1 and CTLA-4 inhibition to oxaliplatin, fluorouracil and leucovorin (FOLFOX

2018 ESMO open

117. Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer Full Text available with Trip Pro

Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer Purpose Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients with colorectal cancer (CRC) and type II diabetes mellitus (DM). Although type II DM and CRC are major health problems in the Middle East, no investigations have been performed to test the effect metformin has on the outcome of patients (...) with type II DM and CRC who are also treated with metformin. Materials and Methods We retrospectively reviewed the medical records of 1,902 patients diagnosed with CRC at King Hussein Cancer Center between January 2004 and December 2012, and identified 349 patients (18%) with type II DM; we censored the data of 28 patients because their antidiabetic medications were unknown. We then categorized these 321 patients into two groups: 192 patients treated with metformin (group A) and 129 patients treated

2018 Journal of global oncology

118. Clonal evolution of colorectal cancer in a patient with serially resected metastases and liquid biopsies: a case report and discussion of the literature Full Text available with Trip Pro

Clonal evolution of colorectal cancer in a patient with serially resected metastases and liquid biopsies: a case report and discussion of the literature Metastatic colorectal cancer represents a striking example of clonal heterogeneity and tumour evolution, which generates acquired resistance to therapy. Once hard to perform, the study of clonal heterogeneity is now significantly aided by the use of liquid biopsies.We herein report a case of a patient with colorectal cancer and serial (...) development of multiple metastases which were all resected and genotyped. A rare point mutation was identified in the primary tumour (but not in any of the organ metastatic sites), as well as in the first and the last out of three consecutive liquid biopsies. The review of the literature offered some insight in the evolution of the patient's tumour and general directions on how to interpret liquid biopsy results.This patient case emphasises the need for large prospective studies designed to bridge liquid

2018 ESMO open

119. Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities Full Text available with Trip Pro

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities A meta-analysis of sociodemographic variables and their association with late (>180 days from start of radiation therapy[RT]) bowel, bladder, and clustered bowel and bladder toxicities was conducted in patients with high-risk (clinical stages T2c-T4b or Gleason score 8-10 or prostate-specific antigen level >20) prostate cancer.Three NRG (...) received prostate-only RT+HT had a lower risk of experiencing grade ≥2 bowel toxicities than those who received whole-pelvic RT+long-term (LT) HT (hazard ratio: 0.36; 95% confidence interval, 0.18-0.73; P = .0046 and hazard ratio: 0.43; 95% confidence interval, 0.23-0.80; P = .008, respectively). Patients who received whole-pelvic RT had similar chances of having grade ≥2 bowel or bladder toxicities no matter whether they received LT or short-term HT.Patients with high-risk prostate cancer who receive

2018 Advances in radiation oncology

120. Assessing Clinical Outcomes in Colorectal Cancer with Assays for Invasive Circulating Tumor Cells Full Text available with Trip Pro

Assessing Clinical Outcomes in Colorectal Cancer with Assays for Invasive Circulating Tumor Cells Colorectal carcinoma (CRC) is the second leading cause of cancer-related mortality. The goals of this study are to evaluate the association between levels of invasive circulating tumor cells (iCTCs) with CRC outcomes and to explore the molecular characteristics of iCTCs. Peripheral blood from 93 patients with Stage I⁻IV CRC was obtained and assessed for the detection and characterization of iCTCs (...) using a functional collagen-based adhesion matrix (CAM) invasion assay. Patients were followed and assessed for overall survival. Tumor cells isolated by CAM were characterized using cell culture and microarray analyses. Of 93 patients, 88 (95%) had detectable iCTCs, ranging over 0⁻470 iCTCs/mL. Patients with Stage I⁻IV disease exhibited median counts of 0.0 iCTCs/mL (n = 6), 13.0 iCTCs/mL (n = 12), 41.0 iCTCs/mL (n = 12), and 133.0 iCTCs/mL (n = 58), respectively (p < 0.001). Kaplan⁻Meier curve

2018 Biomedicines